Life Technologies Supports Global Effort to Help Accelerate Emergency Screening of Novel Middle East Respiratory Syndrome

    Life Technologies Supports Global Effort to Help Accelerate Emergency
  Screening of Novel Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

PR Newswire

CARLSBAD, Calif., June 26, 2013

CARLSBAD, Calif., June 26, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) announces that its Applied Biosystems® 7500 Fast Dx Real-Time
PCR instrument is suitable for use with the CDC Novel Coronavirus 2012
Real-time RT-PCR Assay, which has received Emergency Use Authorization for
detection in patient specimens of the novel Middle East Respiratory Syndrome
Coronavirus (MERS-CoV). To date the virus has been found in Jordan, Qatar,
Saudi Arabia, the United Arab Emirates (UAE), France, Germany, Italy, Tunisia
and the United Kingdom. Globally, since September 2012, the World Health
Organization (WHO) has been informed of a total of 64 laboratory-confirmed
cases of the infection with MERS-CoV, including 38 deaths.

Additionally, the CDC Novel Coronavirus 2012 Assay can be performed using
Life's SuperScript III One-Step qRT-PCR reagent kit. The Respiratory Syndrome
Coronavirus (MERS-CoV) Assay is intended to quickly monitor the spread of the
pathogen and thwart a potential pandemic. To support this global need, Life
Technologies is increasing production of its reagents and shipping them to
labs around the world. This test has been authorized only for the diagnosis of
Respiratory Syndrome Coronavirus (MERS-CoV) and not for the diagnosis of any
other viruses or pathogens.

"We are working continually with our partners to improve capabilities,
particularly tests that work more quickly and simply on more people," said
Mark Stevenson, president and chief operating officer at Life
Technologies."Our technology aids public health labs around the globe to
identify threats and develop rapid detection kits."

The test has been authorized by FDA under an Emergency Use Authorization for
use by qualified laboratories. The CDC Novel Coronavirus 2012 Assay has not
been FDA cleared or approved.

The CDC Novel Coronavirus 2012 Assay is only authorized for the duration of
the declaration that circumstances exist justifying the authorization of the
emergency use of in vitro diagnostics for detection of MERS-CoV under section
564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.Csection

Last year, Life Technologies established the Global Influenza Network, a
partnership of scientists at a number of the world's leading government public
health organizations, veterinary agencies and research institutes who
collaborate in an effort to increase the speed and efficiency of influenza
monitoring and vaccine development.This network builds upon Life
Technologies' strong history of working with the CDC, the WHO and public
health labs to combat virus outbreaks:

  oLast month, the company's 7500 Fast Dx Real-Time PCR instrument was
    indicated as the sole instrument for use with the CDC's influenza A
    (H7/N9) virus, which received emergency use authorization for detection in
    patient specimens of the novel influenza A (H7/N9) virus.
  oIn 2011, the company developed a custom assay to accurately detect the E.
    coli bacterium that spread through Europe. The assay was developed after
    company researchers, using samples supplied by scientists at University
    Hospital Munster, completed the DNA sequencing and analysis work on the
    deadly E. coli strain using the Ion PGM™ Sequencer.
  oIn 2009, Life Technologies formed a special 24-hour-a-day task force to
    respond to global requests for assistance with the H1N1 outbreak.

The SuperScript III One-Step qRT-PCR kit is for research use only; not for use
in diagnostic procedures.

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Media Contact:
Suzanne Clancy
858-205-4235 (mobile)

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.